Market

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through
Read More

Related Posts

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

SS&C Technologies director Michael Zamkow sells $2.03 million in stock

SS&C Technologies director Michael Zamkow sells $2.03 m...

Japan factory output contracts as expected in Jan, retail sales jump

Japan factory output contracts as expected in Jan, reta...

Dollar firms as Trump's tariffs loom, yen set for monthly gain

Dollar firms as Trump's tariffs loom, yen set for month...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

Virgin Galactic’s new spacecraft looms large as company eyes future profitability

Virgin Galactic’s new spacecraft looms large as company...